The LRRK2 is a large protein (2527 amino acids) with serine-threonine (Ser/Thr) protein kinase activity and autophosphorylation activity. It is highly expressed in many mammal tissues. Genetic mutations in the G2019S encoding portion of LRRK2 (LRRK2-G2019S) have been detected frequently in Parkinson's (PD) patients.1) As a result, LRRK2-G2019S is a promising therapeutic target for the treatment of PD, and its inhibitors have been used as useful tools in PD research.2,3,4) For more information, please refer to the application information of product detail page on our website.
References
1) Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors